LyGenesis, Inc., a Pittsburgh, PA-based biotechnology company developing innovative technology for organ regeneration, raised $3m in Series A financing.
Juvenescence, Ltd., made the investment. In conjunction with the funding, Greg Bailey, MD, Co-Founder and CEO of Juvenescence, will be joining LyGenesis’ Board of Directors.
The financing will enable the company to complete the final preclinical work required to enable human clinical trials, which will initially focus on patients with end stage liver disease.
Built on academic research by Eric Lagasse, PharmD, PhD, Associate Professor in the Department of Pathology at the University of Pittsburgh and LyGenesis’ Chief Scientific Officer, and led by Michael Hufford, PhD, Chief Executive Officer, and Professor of Surgery, and Paulo Fontes, MD, FACS, Chief Medical Officer, LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient’s lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Its lead preclinical program is focused on liver regeneration for patients with end stage liver disease. Other therapeutic targets for organ regeneration include the thymus, pancreas, and kidney.